Evidence map›Paper›PMID 27416912›Full record

Trial reportLeukemia2017

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).

R Hájek, T Masszi, M T Petrucci, A Palumbo, L Rosiñol, A Nagler, K L Yong, A Oriol, J Minarik, L Pour and 22 more

Open access · hybridAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 5 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 5 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Observational
  19. Article
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 20 institutions in 13 countries.

R HájekUniversity Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
T MassziSt István and St László Hospital of Budapest, Budapest, Hungary.
M T PetrucciSapienza University of Rome, Rome, Italy.
A PalumboUniversity of Torino, Torino, Italy.
L RosiñolHospital Clínic de Barcelona, Barcelona, Spain.
A NaglerChaim Sheba Medical Center, Tel Hashomer, Israel.
K L YongUniversity College London Cancer Institute, London, UK.
A OriolInstitut Català d'Oncologia, Hospital Germans Trias i Pujol, Barcelona, Spain.
J MinarikUniversity Hospital Olomouc and Medical Faculty of Palacky, University Olomouc, Olomouc, Czech Republic.
L PourUniversity Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
M A DimopoulosNational and Kapodistrian University of Athens, Athens, Greece.
V MaisnarCharles University Teaching Hospital, Hradec Králové, Czech Republic.
D RossiAmedeo Avogadro University of Eastern Piedmont, Novara, Italy.
H KasparuHospital Elisabethinen Linz, Linz, Austria.
J Van DroogenbroeckAZ Sint-Jan, Brugge, Belgium.
D B YehudaHadassah Medical Center, Jerusalem, Israel.
I HardanMeir Medical Center, Kfar-Saba, Israel.
M JennerSouthampton General Hospital, Hampshire, UK.
M CalbeckaNicolaus Copernicus Hospital, Toruń, Poland.
M DávidUniversity of Pécs, Pécs, Hungary.
J de la RubiaUniversity Hospital La Fe and Universidad Católica de València 'San Vicente Mártir', València, Spain.
J DrachMedical University of Vienna, Vienna, Austria.
Z GasztonyiPetz Aladár Megyei Oktató Kórház, Vasvári Pál, Hungary.
S GórnikZamojski Szpital Niepubliczny, Zamosc, Poland.
X LeleuHopital Huriez, CHRU, Lille, France.
M MunderUniversity Medicine Mainz, Mainz, Germany.
M OffidaniClinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Ancona, Italy.
N ZojerCenter for Oncology, Hematology with Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria.
K RajangamOnyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA.
Y-L ChangOnyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA.
J F San-MiguelClínica Universidad de Navarra-CIMA-IDISNA, Navarra, Spain.
H LudwigWilhelminen Cancer Research Institute, Vienna, Austria.
Amgen (United States) · USUniversity of Ostrava · CZWilhelminen Hospital · ATAzienda Ospedaliero Universitaria Ospedali Riuniti · ITAZ Sint-Jan · BECharles University · CZClinica Universidad de Navarra · ESHadassah Medical Center · ILHôpital Claude Huriez · FRHospital Clínic de Barcelona · ESInstitut Català d'Oncologia · ESJohannes Gutenberg University Mainz · DEKrankenhaus der Elisabethinen · ATLondon Cancer · GBMedical University of Vienna · ATMeir Medical Center · ILNational and Kapodistrian University of Athens · GRNicolaus Copernicus University · PLPetz Aladár Megyei Oktató Kórház · HUSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). Relapsed and refractory multiple myeloma patients were randomized (1:1) to receive carfilzomib (10-min intravenous infusion; 20 mg/m

Indexed as

Adrenal Cortex HormonesAdultAgedAged, 80 and overAnemiaCyclophosphamideDisease-Free SurvivalFemaleHumansMaleMiddle AgedMultiple MyelomaNeutropeniaOligopeptidesRecurrenceSalvage TherapyAdrenal Cortex HormonescarfilzomibCyclophosphamideOligopeptides

Identifiers

PMID27416912
PMCPMC5220126
OpenAlexW2460673902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.